Norcantharidin enhances TIMP-2 anti-vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP-2 and MT1-MMP

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 627-640

  Zhu, Wei ^a,b   Sun, Wei ^a   Zhang, Jing Tao ^a   Liu, Zhong Yan ^a   Li, Xin Ping ^a   Fan, Yue Zu ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Dahua Hospital   (China)

Author keywords

Anti vasculogenic mimicry therapy; Gallbladder neoplasm; Matrix metalloproteinase; Norcantharidin; Vasculogenic mimicry

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; NORCANTHARIDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; FUSED HETEROCYCLIC RINGS; MMP2 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL AGGREGATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; GALLBLADDER CANCER; HEMODYNAMICS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICROCIRCULATION; MICROVILLUS; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULOGENIC MIMICRY; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GALLBLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MICE; NEOVASCULARIZATION, PATHOLOGIC; TISSUE INHIBITOR OF METALLOPROTEINASE-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918503704     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2753     Document Type: Article

References (50)

1. Lazcano-Ponce EC, Miquel JF, Muñoz N, et al: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51: 349-364, 2001.
2. Reddy SK and Clary BM: Surgical management of gallbladder cancer. Surg Oncol Clin N Am 18: 307-324, 2009.
3. Chakravarty KD, Yeh CN, Jan YY and Chen MF: Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 79: 151-157, 2009.
4. Ishii H, Furuse J, Yonemoto N, et al: Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 66: 138-142, 2004.
5. Mahantshetty UM, Palled SR, Engineer R, et al: Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther 2: 52-56, 2006.
6. Maniotis AJ, Folberg R, Hess A, et al: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752, 1999.
7. Warso MA, Maniotis AJ, Chen X, et al: Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7: 473-477, 2001.
8. Tian F, Zhang X, Tong Y, et al: PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol Ther 4: 874-882, 2005.
9. Zhou YX and Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) 122: 1666-1673, 2009.
10. Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun W: Norcantharidin: A potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol 40: 1501-1514, 2012.
11. Zhang S, Li M, Gu Y, et al: Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res 27: 60, 2008.
12. Cong R, Sun Q, Yang L, et al: Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 28: 124, 2009.
13. Fu D, He X, Yang S, et al: Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro. BMC Musculoskelet Disord 12: 146, 2011.
14. Chen LX, He YJ, Zhao SZ, et al: Inhibition of tumor growth and vasculogenic mimicry by curcumin through downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 11: 229-235, 2011.
15. Chen HX and Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477, 2009.
16. Higa GM and Abraham J: Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 9: 999-1007, 2009.
17. van der Schaft DW, Seftor RE, Seftor EA, et al: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96: 1473-1477, 2004.
18. McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6: 149-156, 2000.
19. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241, 1999.
20. Sood AK, Fletcher MS, Coffin JE, et al: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190: 899-909, 2004.
21. Hess AR, Seftor EA, Seftor RE and Hendrix MJ: Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63: 4757-4762, 2003.
22. Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V and Seftor RE: Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci 995: 151-161, 2003.
23. Albini A, Melchiori A, Santi L, et al: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83: 775-779, 1991.
24. Seftor RE, Seftor EA, Koshikawa N, et al: Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/ metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61: 6322-6327, 2001.
25. Fan YZ, Sun W, Zhang WZ and Ge CY: Vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi 87: 145-149, 2007 (In Chinese).
26. Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ, Zhang JT, Lu XS and Ye C: Overexpression of HIF- 1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep 27: 1990-2002, 2012.
27. Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res 30: 46, 2011.
28. Lu XS, Sun W, Ge CY, Zhang WZ and Fan YZ: Contribution of the PI3-K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol 42: 2103-2115, 2013.
29. Wang GS: Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 26: 147-162, 1989.
30. Liu J, Gao J and Liu X: Advances in the study of Cantharidin and its derivatives. Zhong Yao Cai 26: 453-455, 2003.
31. Ho YP, To KK, Au-Yeung SC, et al: Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 44: 2065-2068, 2001.
32. Yang EB, Tang WY, Zhang K, Cheng LY and Mack PO: Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 117: 93-98, 1997.
33. Yi SN, Wass J, Vincent P and Iland H: Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 15: 883-886, 1991.
34. An WW, Wang MW, Tashiro S, Onodera S and Ikejima T: Norcantharidin induces human melanoma A375-S2 cell apoptosis through mitochondrial and caspase pathways. J Korean Med Sci 19: 560-566, 2004.
35. Fan YZ, Fu JY, Zhao ZM and Chen CQ: Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC- SD cells in vitro. Hepatobiliary Pancreat Dis Int 6: 72-80, 2007.
36. Fan YZ, Zhao ZM, Fu JY, Chen CQ and Sun W: Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int 9: 414-422, 2010.
37. Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY, Zhao ZM, Lu XS and Fan YZ: Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway. BMC Cancer 14: 193, 2014.
38. Wang H, Sun W, Zhang WZ, Ge CY, Zhang JT, Liu ZY and Fan YZ: Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/Paxillin signaling pathway. PLoS One 9: e96982, 2014.
39. McNamara MG, Metran-Nascente C and Knox JJ: State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol 25: 425-431, 2013.
40. Li M, Gu Y, Zhang Z, et al: Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16: 259-266, 2010.
41. Wang CJ, Zhou ZG, Holmqvist A, et al: Survivin expression quantified by Image Pro-Plus compared with visual assessment. Appl Immuohistochem Mol Morphol 17: 530-535, 2009.
42. Xavier LL, Viola GG, Ferraz AC, et al: A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Protoc 16: 58-64, 2005.
43. Situ DR, Hu Y, Zhu ZH, et al: Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol 16: 5195-5202, 2010.
44. Zlobec I, Steele R, Terracciano L, Jass JR and Lugli A: Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60: 1112-1116, 2007.
45. Kilkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412, 2010.
46. Fan YZ and Sun W: Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2: 117-127, 2010.
47. Seftor RE, Seftor EA, Kirschmann DA and Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1: 1173-1179, 2002.
48. Hess AR, Seftor EA, Gardner LM, et al: Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 3250-3255, 2001.
49. Margaryan NV, Strizzi L, Abbott DE, et al: EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8: 279-288, 2009.
50. Hess AR and Hendrix MJ: Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 5: 478-480, 2006.